AR038915A1 - Derivados de aminoindazoles, procedimiento de preparacion e intermedios de este procedimiento, medicamentos y composiciones farmaceuticas que contienen al compuesto - Google Patents

Derivados de aminoindazoles, procedimiento de preparacion e intermedios de este procedimiento, medicamentos y composiciones farmaceuticas que contienen al compuesto

Info

Publication number
AR038915A1
AR038915A1 ARP030100808A ARP030100808A AR038915A1 AR 038915 A1 AR038915 A1 AR 038915A1 AR P030100808 A ARP030100808 A AR P030100808A AR P030100808 A ARP030100808 A AR P030100808A AR 038915 A1 AR038915 A1 AR 038915A1
Authority
AR
Argentina
Prior art keywords
aryl
alkyl
heteroaryl
formula
nr8r9
Prior art date
Application number
ARP030100808A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AR038915A1 publication Critical patent/AR038915A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Abstract

Estos compuestos pueden ser utilizados para prevenir y tratar enfermedades que pueden resultar de una actividad normal de kinasas, como por ejemplo, las enfermedades neurodegenerativas (tales como enfermedades de Alzheimer, Parkinson, Pick, la demencia frontoparietal, los accidentes cerebrovasculares y los traumatismos craneales, entre otras). Reivindicación 1: Compuestos de fórmula (1), en la que: R es bien O, S o NH; R3 es un radical alquilo (C1-6), arilo, arilo-alquilo(C1-6), heteroarilo, heteroarilo-alquilo(C1-6), arilo o heteroarilo fusionado con un cicloalquilo (C1-10), heterociclo, cicloalquilo, adamantilo, policicloalquilos, alquenilo, alquinilo; estando estos radicales, eventualmente, sustituidos por 1 o varios sustituyentes elegidos entre halógeno, CN, NO2, NH2, OH, OR8, COOH, C(O)OR8, -O-C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, SR8, S(O)R8, SO2R8, NHSO2R8, SO2NR8R9, C(S)NR8R9, NHC(S)R8, -O-SO2R8, -SO2-O-R8, arilo, heteroarilo, formilo, triflúormetilo, triflúormetilsulfanilo, trifluormetoxi; R4, R5, R6 y R7 son elegidos, independientemente entre sí, entre los radicales siguientes hidrógeno, halógeno, CN, NO2, NH2, OH, COOH, C(O)OR8, -O-C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO2R8, NHSO2R8, SO2NR8R9, -O-SO2R8, -SO2-O-R8, triflúormetilo, triflúormetoxi, alquilo (C1-6),alcoxi (C1-6), arilo, arilo-alquilo(C1-6), heteroarilo, heteroarilo-alquilo(C1-6), heterociclo, cicloalquilo, alquenilo, alquinilo, adamantilo, policicloalquilos; estando sustituidos estos radicales, eventualmente, por 1 o varios sustituyentes elegidos entre halógeno, CN, NO2, NH2, OH, OR10, COOH, C(O)OR10, -O-C(O)R10, NR10R11, NHC(O)R10, C(O)NR10R11, NHC(S)R10, C(S)NR10R11, SR10, S(O)R10, SO2R10, NHSO2R10, SO2NR10R11, -O-SO2R10, -SO2-O-R10, arilo, heteroarilo, formilo, triflúormetilo, triflúormetoxi; R8, R9, R10, R11 son, independientemente entre sí, un hidrógeno, alquilo (C1-6), arilo, alquenilo, alquinilo, heteroarilo estando a su vez, eventualmente sustituidos por 1 o varios sustituyentes elegidos entre halógeno, alquilo(C1-6), alcoxi (C1-6), CN, NO2, NH2, OH, COOH, COOalquilo, CONH2, formilo, triflúormetilo, triflúormetoxi; sus racémicos, enantiómeros, diastereoisómeros y sus mezclas, sus tautómeros y sus sales farmacéuticamente aceptables para preparar un medicamento. Reivindicación 13: Procedimiento para la preparación de los compuestos de fórmula (1) tales como los que se han definido en la reivindicación 1 en los que R es oxígeno caracterizado porque se efectúa una acilación del derivado amina de fórmula (2), en la que R4, R5, R6, R7 tienen los mismos significados que en la reivindicación 1, transformándose, eventualmente, en sal farmacéuticamente aceptable. Reivindicación 14: Procedimiento para la preparación de los compuestos de fórmula (1) tales como los que se han definido en la reivindicación 1 y en los que R es un azufre caracterizado porque se efectúa una tionación del derivado en el que R es un oxígeno, transformándose, eventualmente, en sal farmacéuticamente aceptable. Reivindicación 15: Procedimiento para la preparación de los compuestos de fórmula (1) tales como los que se han definido en la reivindicación 1 y en los que R es NH, caracterizado porque se efectúa una reacción del derivado de fórmula (2) con un nitrilo o sal de Merwein en la que R4, R5, R6, R7 tienen los mismos significados que en la reivindicación 1 transformándose, eventualmente, en sal farmacéuticamente aceptable. Reivindicación 16: Procedimiento de preparación según las reivindicaciones 13 y 15 caracterizado porque el derivado de fórmula (2) se obtiene a partir del derivado de fórmula (3) por reacción con hidrazina.
ARP030100808A 2002-03-11 2003-03-10 Derivados de aminoindazoles, procedimiento de preparacion e intermedios de este procedimiento, medicamentos y composiciones farmaceuticas que contienen al compuesto AR038915A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0202997A FR2836915B1 (fr) 2002-03-11 2002-03-11 Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
AR038915A1 true AR038915A1 (es) 2005-02-02

Family

ID=27763685

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100808A AR038915A1 (es) 2002-03-11 2003-03-10 Derivados de aminoindazoles, procedimiento de preparacion e intermedios de este procedimiento, medicamentos y composiciones farmaceuticas que contienen al compuesto

Country Status (30)

Country Link
US (1) US6949579B2 (es)
EP (1) EP1487804B1 (es)
JP (2) JP4648630B2 (es)
KR (1) KR101068770B1 (es)
CN (2) CN101962365A (es)
AR (1) AR038915A1 (es)
AU (1) AU2003242809B8 (es)
BR (1) BR0308373A (es)
CA (1) CA2478542C (es)
FR (1) FR2836915B1 (es)
GT (1) GT200300057A (es)
HR (1) HRP20040824B1 (es)
IL (2) IL163831A0 (es)
JO (1) JO2326B1 (es)
MA (1) MA27230A1 (es)
ME (2) MEP16108A (es)
MX (1) MXPA04007478A (es)
MY (1) MY138269A (es)
NO (1) NO329384B1 (es)
NZ (1) NZ535147A (es)
PA (1) PA8568301A1 (es)
PE (1) PE20040155A1 (es)
PL (1) PL370478A1 (es)
RS (1) RS52396B (es)
RU (1) RU2345070C2 (es)
SV (1) SV2003001494A (es)
TW (1) TWI329103B (es)
UY (1) UY27713A1 (es)
WO (1) WO2003078403A2 (es)
ZA (1) ZA200406687B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
ES2411655T3 (es) * 2002-05-17 2013-07-08 Pfizer Italia S.R.L. Derivados de aminoindazol activos como inhibidores de quinasas, procedimiento para su preparación y composiciones farmacéuticas que los comprenden
MXPA05001807A (es) 2002-09-05 2005-04-19 Aventis Pharma Sa Nuevos derivados de aminoindazol utilizados como medicamentos y composiciones farmaceuticas que los contienen.
CN100439341C (zh) 2002-12-02 2008-12-03 弗·哈夫曼-拉罗切有限公司 作为促肾上腺皮质激素释放因子拮抗剂的吲唑衍生物
FR2848554A1 (fr) * 2002-12-12 2004-06-18 Aventis Pharma Sa Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
EP1572200B1 (fr) * 2002-12-12 2011-08-17 Aventis Pharma S.A. Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
ES2564804T3 (es) 2004-02-12 2016-03-29 Mitsubishi Tanabe Pharma Corporation Compuesto de indazol y uso farmacéutico del mismo
FR2871158A1 (fr) * 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
GT200500208A (es) 2004-08-03 2006-03-02 Indazoles ùtiles para tratar enfermedades cardiovasculares
CA2621983A1 (en) * 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
RU2442777C2 (ru) 2006-01-31 2012-02-20 Эррэй Биофарма Инк. Ингибиторы киназ и способы их применения
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
PL2120932T3 (pl) * 2006-12-20 2015-02-27 Nerviano Medical Sciences Srl Indazolowe pochodne jako inhibitory kinazy do leczenia raka
DE102007022565A1 (de) * 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
NZ583450A (en) * 2007-07-20 2012-05-25 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101977905B (zh) 2008-01-23 2014-07-02 百时美施贵宝公司 4-吡啶酮化合物及其对于癌症的用途
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2630026T3 (es) * 2008-12-18 2017-08-17 Nerviano Medical Sciences S.R.L. Derivados indazólicos sustituidos activos como inhibidores de cinasa
JO3025B1 (ar) 2009-04-30 2016-09-05 Glaxo Group Ltd الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EA201290919A1 (ru) * 2010-03-16 2013-03-29 Дана-Фарбер Кэнсер Инститьют, Инк. Индазольные соединения и их применение
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
JP6298765B2 (ja) * 2011-12-27 2018-03-20 バイオ−ファーム ソリューションズ カンパニー リミテッド 脳卒中の治療または予防に使用されるするためのフェニルカルバメート化合物
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
CN103739550B (zh) * 2014-01-02 2016-06-01 中国药科大学 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用
CA2937111A1 (en) * 2014-01-24 2015-07-30 Abbvie Inc. 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
KR101731624B1 (ko) 2014-07-01 2017-05-04 광주과학기술원 세포 리프로그래밍 유도용 조성물
PE20170774A1 (es) * 2014-08-19 2017-07-04 Shanghai Haihe Pharmaceutical Co Ltd Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
EP3236959A4 (en) 2014-12-23 2018-04-25 Dana Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN106279119B (zh) * 2015-05-27 2020-06-16 上海海和药物研究开发有限公司 一种新型激酶抑制剂的制备及其应用
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
EP3365337A1 (en) * 2015-10-22 2018-08-29 Selvita S.A. Pyridone derivatives and their use as kinase inhibitors
CN105467027B (zh) * 2015-11-18 2021-09-21 北京万全德众医药生物技术有限公司 一种用气相色谱法分离测定米诺膦酸中间体有关物质的方法
JP7061068B2 (ja) 2015-12-18 2022-04-27 イグナイタ インコーポレイテッド 癌治療のための併用薬
AU2018302170B2 (en) 2017-07-19 2024-02-29 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
BR112020002265A2 (pt) 2017-08-01 2020-07-28 Theravance Biopharma R&D Ip, Llc compostos pirazólicos e triazólicos bicíclicos como inibidores de jak quiinase
WO2019077506A1 (en) 2017-10-17 2019-04-25 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS
JP2022505707A (ja) * 2018-10-24 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 置換インドールおよびインダゾール化合物
EP3914348A1 (en) 2019-01-23 2021-12-01 Theravance Biopharma R&D IP, LLC Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
US20230053607A1 (en) * 2019-12-04 2023-02-23 Syngenta Crop Protection Ag Pesticidally active fused bicyclic heteroaromatic amino compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133081A (en) * 1964-05-12 J-aminoindazole derivatives
US2971842A (en) * 1956-03-21 1961-02-14 Gen Aniline & Film Corp Light sensitive layers for photomechanical reproduction
DE1280878B (de) * 1961-11-30 1968-10-24 Smith Kline French Lab 3-Aminoindazole
GB965511A (en) * 1961-11-30 1964-07-29 Smith Kline French Lab Improvements in or relating to 3-aminoindazole derivatives
BE626284A (es) * 1962-04-28
US3720671A (en) * 1970-10-05 1973-03-13 Ciba Geigy Ag Polycyclic dyestuffs
FR2111641A2 (en) * 1970-10-09 1972-06-09 Geigy Ag J R Polycyclic cpds as dispersion dyestuffs for - hydrophobic organic fibres
DE2458965C3 (de) * 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
JPS51143010A (en) * 1975-06-04 1976-12-09 Kao Corp Stable bleaching detergent composition
SU742430A1 (ru) * 1978-11-09 1980-06-25 Предприятие П/Я А-7850 Способ получени 3-амино-5-нитроиндазола
JPS58159473A (ja) * 1982-03-17 1983-09-21 Asahi Chem Ind Co Ltd ベンゼン環置換基を有する新規な１位置換インダゾ−ル誘導体およびその製造法
US4533731A (en) * 1982-03-17 1985-08-06 Asahi Kasei Kogyo Kabushiki Kaisha Aminoindazole derivatives
KR940021073A (ko) * 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸

Also Published As

Publication number Publication date
CA2478542C (fr) 2012-02-21
PA8568301A1 (es) 2005-02-04
FR2836915A1 (fr) 2003-09-12
AU2003242809A1 (en) 2003-09-29
KR101068770B1 (ko) 2011-09-30
JO2326B1 (en) 2006-06-28
NO20044137L (no) 2004-11-25
RS79504A (en) 2006-12-15
CN1656078A (zh) 2005-08-17
PE20040155A1 (es) 2004-04-18
JP5315287B2 (ja) 2013-10-16
PL370478A1 (en) 2005-05-30
EP1487804B1 (fr) 2014-02-26
AU2003242809B2 (en) 2010-03-18
NO329384B1 (no) 2010-10-11
WO2003078403A2 (fr) 2003-09-25
CA2478542A1 (fr) 2003-09-25
FR2836915B1 (fr) 2008-01-11
BR0308373A (pt) 2005-01-11
HRP20040824A2 (en) 2005-06-30
CN101962365A (zh) 2011-02-02
RS52396B (en) 2013-02-28
MEP16108A (en) 2010-06-10
JP2010222357A (ja) 2010-10-07
ME00058B (me) 2010-10-10
MY138269A (en) 2009-05-29
EP1487804A2 (fr) 2004-12-22
SV2003001494A (es) 2003-07-10
TWI329103B (en) 2010-08-21
US6949579B2 (en) 2005-09-27
MXPA04007478A (es) 2004-11-10
ZA200406687B (en) 2005-10-26
UY27713A1 (es) 2003-09-30
IL163831A (en) 2010-12-30
MA27230A1 (fr) 2005-02-01
NZ535147A (en) 2007-08-31
AU2003242809B8 (en) 2010-04-15
TW200403226A (en) 2004-03-01
RU2004129780A (ru) 2005-04-10
US20040014802A1 (en) 2004-01-22
IL163831A0 (en) 2005-12-18
GT200300057A (es) 2006-10-19
JP4648630B2 (ja) 2011-03-09
HRP20040824B1 (hr) 2013-05-31
JP2005530711A (ja) 2005-10-13
WO2003078403A3 (fr) 2004-04-22
KR20040091121A (ko) 2004-10-27
RU2345070C2 (ru) 2009-01-27

Similar Documents

Publication Publication Date Title
AR038915A1 (es) Derivados de aminoindazoles, procedimiento de preparacion e intermedios de este procedimiento, medicamentos y composiciones farmaceuticas que contienen al compuesto
NZ610312A (en) 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
AR045389A1 (es) Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
AR079541A1 (es) Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms
RS28004A (en) Azabicycle-substituted fused- heteroaryl compounds for the treatment of disease
AR039566A1 (es) Inhibidores de la histona deacetilasa, composicion farmaceutica que los contiene y sus procesos de preparacion
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
HUP0402454A2 (hu) Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE545413T1 (de) Antagonisten des opioidrezeptors
NO20071140L (no) Nye piperidinderivater som histamin H3 reseptorligander for behandling av depresjon
MY134666A (en) Pyridinoylpiperidines as 5-ht1f agonists
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
IL172993A0 (en) Thiazolo-,oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases
HUP0203228A2 (hu) Szubsztituált indolszármazékok az NFKB-aktivitás módosítására, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PE20071132A1 (es) Compuestos macrociclicos como inhibidores del factor viia
MX2010001080A (es) Pirrolidin-aril-eteres como antagonistas de receptor de nk3.
AR034203A1 (es) Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento
ATE540037T1 (de) Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
AR066972A1 (es) Derivados azapeptidicos
HUP0302770A2 (hu) Tripeptidil peptidáz inhibitorok, eljárás az előállítására és ezeket tartalmazó gyógyszerkészítmények
TW200500343A (en) Caspase inhibitors and uses thereof
PE20061062A1 (es) Derivados de indazol como inhibidores de los transportadores de norepinefrina y serotonina

Legal Events

Date Code Title Description
FB Suspension of granting procedure